ArticlePDF Available

Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial

Authors:
  • Independent Researcher
  • Complife Italia S.r.l.

Abstract

Background: Hair loss in both men and women can be a psychologically stressful condition. Dietary insufficiency of essential micronutrients has been associated with hair health and hair loss. Objective: The aim of this clinical trial was to investigate the safety of use and the efficacy of a food supplement containing L-cystine, Serenoa repens, Equisetum extract, zinc, and vitamins (Lambdapil® Anti Hair Loss capsules, ISDIN, Provençals, Barcelona, Spain) in improving hair loss in both women and men. Patients/Methods: Men with androgenic alopecia and women with acute telogen effluvium were randomized to receive two capsules per day of the test product or the placebo product during a 6 months treatment period. Hair resistance to pulling and count were measured in women and men, respectively, by pull testing and phototrichogram. The overall hair volume and overall hair appearance were assessed before and after the treatment as were subject’s self-assessment via a standardized questionnaire. Results: In women, the number of hairs removed in the pull test decreased earlier for test product treated group over the 6-month period with a significantly greater decrease (p<0.05) for the treated group (12.9 at baseline vs. 6.5 hairs at 6 M) compared to the placebo group (12.8 at baseline vs. 8.8 hairs at 6 M). For men, the anagen/telogen ratio increased in the Lambdapil® treated group by 22.3% over baseline (1.93 vs. 2.36 at baseline and 6 M, respectively) indicating that there were more hair in the growing phase vs. placebo treated group (1.81 vs 1.75 at baseline and 6 M, respectively; p<0.05). The hair volume and aspect in Lambdapil® treated group improved at 1, 3 and 6 months significantly more than placebo group (p<0.05). The treatment was well tolerated. Conclusion: Dietary supplementation with Lambdapil® Anti Hair Loss capsules for 6-months was safe and effective in both women and men suffering from hair loss.
Efficacy and Safety of a Food Supplement Containing L-cystine,
Serenoa
repens
Extract and Biotin for Hair Loss in Healthy Males and Females. A
Prospective, Randomized, Double-blinded, Controlled Clinical Trial
Mridvika Narda1*, Sonia Aladren1, Enza Cestone2 and Vincenzo Nobile2
1ISDIN SA, ISDIN Medical Department, Provencals 33, 08019 Barcelona, Spain
2Complife Italia Srl, Via Mons Angelini 21, 27028 San Martino Siccomario (PV), Italy
*Corresponding author: Mridvika Narda, ISDIN SA, ISDIN Medical Department, Provencals 33, 08019 Barcelona, Spain, E-mail: mridvika.narda@isdin.com
Received date: November 07, 2017; Accepted date: November 29, 2017; Published date: November 30, 2017
Copyright: © 2017 Narda M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background: Hair loss in both men and women can be a psychologically stressful condition. Dietary insufficiency
of essential micronutrients has been associated with hair health and hair loss.
Objective: The aim of this clinical trial was to investigate the safety of use and the efficacy of a food supplement
containing L-cystine, Serenoa repens, Equisetum extract, zinc, and vitamins (Lambdapil® Anti Hair Loss capsules,
ISDIN, Provençals, Barcelona, Spain) in improving hair loss in both women and men.
Patients/Methods: Men with androgenic alopecia and women with acute telogen effluvium were randomized to
receive two capsules per day of the test product or the placebo product during a 6 months treatment period. Hair
resistance to pulling and count were measured in women and men, respectively, by pull testing and
phototrichogram. The overall hair volume and overall hair appearance were assessed before and after the treatment
as were subject’s self-assessment via a standardized questionnaire.
Results: In women, the number of hairs removed in the pull test decreased earlier for test product treated group
over the 6-month period with a significantly greater decrease (p<0.05) for the treated group (12.9 at baseline vs. 6.5
hairs at 6 M) compared to the placebo group (12.8 at baseline vs. 8.8 hairs at 6 M). For men, the anagen/telogen
ratio increased in the Lambdapil® treated group by 22.3% over baseline (1.93 vs. 2.36 at baseline and 6 M,
respectively) indicating that there were more hair in the growing phase vs. placebo treated group (1.81 vs 1.75 at
baseline and 6 M, respectively; p<0.05). The hair volume and aspect in Lambdapil® treated group improved at 1, 3
and 6 months significantly more than placebo group (p<0.05). The treatment was well tolerated.
Conclusion: Dietary supplementation with Lambdapil® Anti Hair Loss capsules for 6-months was safe and
effective in both women and men suffering from hair loss.
Keywords: Hair loss; Androgenic alopecia; Acute telogen euvium;
L-cystine;
Serenoa repens
; Biotin
Introduction
Hair loss, represented by acute Telogen Euvium (aTE) in women
and androgenetic Alopecia (AGA) in men, is a frequent reason for
dermatology consultation. Despite their being benign and mild
conditions, the associated psycho-emotional stress may impact the
subjects quality of life, and may sometimes lead to secondary
morbidity [1-3]. e main factors contributing to psycho-emotional
stress are inability to style hair, dissatisfaction with appearance,
concern about the continuing hair loss and concern about others
noticing hair loss [4].
Telogen Euvium (TE) is an increased loss of normal club hairs
that occurs by a perturbation of the hair cycle [5]. Whatever the cause
of hair loss, it results in increased disruption of hair cycle leading to
synchronized telogen shedding. It can occur in both genders, but is
overrepresented in women [6]. aTE was rst described as an acute
onset scalp hair loss occurring 2-3 months aer a triggering event,
which is unidentiable in up to 33% cases [6]. A number of factors
have been implicated in the causation of TE, including high fever,
surgery, hospitalization, hemorrhage, changes in medication,
postpartum emotional stress, seasonal variation (July to October),
changes in medication and heavy metals. However, clear evidence in
their support is lacking [6].
Androgenic alopecia (AGA) is the most common hair loss disorder
[6]. It is characterized by the miniaturization of the large, thick
pigmented terminal hair with a diameter of >0.03 mm to small, ne,
non-pigmented vellus hair with a diameter of 0.03 mm [7]. In most
men, AGA develops with a distinctive "patterned" hair-line recession
[8-10]. It aects 50% of male by the age of 50 years and up to 70% of all
males in the later life [10]. It is caused by the overproduction of 5a-
dihydrotestosterone (5a-DHT), a potent androgen, within the hair
follicle, specically the dermal papilla cells that are the main regulators
of hair growth and are the site of 5a-DHT action [10]. It occurs aer
puberty in men with an inherent sensitivity to the eects of androgens
on androgenetic sensitive scalp hair follicles. It does not develop in
men without testosterone or in men with a genetic deciency of the
J
o
u
r
n
a
l
o
f
C
o
s
m
e
t
o
l
o
g
y
&
T
r
i
c
h
o
l
o
g
y
ISSN: 2471-9323
Journal of Cosmetology & Trichology Narda et al., J Cosmo Trichol 2017, 3:3
DOI: 10.4172/2471-9323.1000127
Research Article Open Access
J Cosmo Trichol, an open access journal
ISSN:2471-9323
Volume 3 • Issue 3 • 127
enzyme 5-alpha-reductase type II which converts testosterone to DHT
[6].
Currently two active pharmacological ingredients are approved by
the US Food and Drug Administration (FDA) for the treatment of
AGA, nasteride and minoxidil. Finasteride acts by inhibiting 5-alpha-
reductase and minoxidil, a potassium channel opener, hypothetically,
acts by widening blood vessels and opening potassium channels, thus
allowing more oxygen, blood, and nutrients to the follicles. Although
both have demonstrated ecacy for the treatment of androgenic
alopecia in men [6], both drugs have side eects and are eective in
less than 50% of the patients. Moreover, some people are intimidated
by the pharmacological approach to treat a non-life-threatening
disease such as alopecia. Food supplements are a non-pharmacological
approach that is easy to t into everyday routine without signicant
side eects to treating this sometimes emotionally taxing condition.
In the present study we tested the ecacy of dietary supplements in
capsule form (Lambdapil® Anti Hair Loss capsules, henceforth
Lambdapil®; currently marketed by Isdin, Spain) containing a unique
combination of plant extracts:
Serenoa repens
extract,
Equisetum
arvense
extract, essential minerals: zinc, vitamins: B3, B5, B6, D-biotin
and amino acids: L-cystine and taurine in improving the signs of
alopecia in both men and women.
Serenoa repens
extract has been
reported to inhibit 5-alpha reductase activity, an enzyme involved in
the hair loss in alopecia [8].
Equisetum arvense
is a plant rich in highly
bioavailable silicon which is purported to aid in improving the
resilience of hair and nails [9]. Other components of the capsules such
as biotin, zinc, amino acids and vitamins are thought to contribute to
the maintenance of normal hair by normalizing protein synthesis
including keratin and collagen synthesis which is essential for hair
growth [11]. Vitamin B6 has been described to contribute to the
regulation of hormonal activity [12]. is combination of plant
extracts, vitamins, trace minerals and amino acids has been designed
to replenish these where a possible deciency might have led to a hair
loss and regulating the hormonal balance to favor hair growth.
e primary objective of this randomized, double-blind, placebo-
controlled study was to assess the ecacy of Lambdapil® capsules in
decreasing the clinical signs of hair loss in female and male subjects.
Materials and Methods
Study design
is monocentric, prospective, randomized, parallel-group, double-
blind, placebo controlled study was carried out in accordance with the
Declaration of Helsinki and the Good Clinical Practice guidelines E6
(R1). e study protocol and the informed consent form were
approved by the “Independent Ethical Committee for Non-
Pharmacological Clinical trials” during its meeting on February 06 th,
2014. is study was not registered as the tested product was a food
supplement. All subjects provided written informed consent and a
consent release for photo publication before initiation of any study-
related procedures. e study took place at Farcoderm s.r.l.
dermatological facilities in San Martino Siccomario (PV), Italy.
Farcoderm s.r.l. is an independent testing laboratory for
in vitro
and
in
vivo
safety and ecacy assessment of cosmetics, food supplements and
medical devices.
Subjects
Eligible subjects were enrolled and screened in the study under the
supervision of a board certied dermatologist. All subjects were adult
Caucasian male and females subjects aged between 18 and 65 years old
showing the clinical signs of AGA grade II to III vertex according to
Hamilton Norwood scale [13] or aTE, respectively. e participants
were enrolled (recruitment and treatment) between March and
September 2014. e inclusion criteria were as follows: i) adequate rest
period between two similar study (at least 6 months from the last
study), ii) willingness to not use products for hair care (both topic and
systemic) likely to interfere with the product to be tested, iii)
willingness to not use, during all the study period, products for hair
care other than the products supplied, iv) willingness to not vary the
normal daily routine (i.e. lifestyle, physical activity, including haircut,
etc.), v) subject under eective contraception (oral/not oral); not
expected to be changed during the trial. Exclusion criteria included
pregnancy or intention to become pregnant, lactation, food
intolerances/allergy, and participation in another similar study within
6 months prior to enrolling in the study, subjects unwilling or unable
to comply with the requirements of the study protocol. e study
further excluded subjects using topical products or food supplements
containing actives that could have an inuence on hair physiology.
Changes in hairstyle or dyeing of the hair were not allowed during the
trial.
Interventions
e tested product was a commercially available food supplement
named Lambdapil® capsules (ISDIN, Provençals, Barcelona, Spain).
e product composition is presented in Table 1. e placebo product
was a 100% maltodextrin capsule. Active and placebo products were
identical in appearance without any visible dierence. Subjects were
instructed to take both the active and the placebo products as follows:
2 capsules a day in the morning at breakfast, to be swallowed as a
whole with plenty of water. For the duration of the study period,
subjects washed their hair using a neutral shampoo.
Components Per 2 capsules %NRV* (2
capsules)
L-Cystine 1000 mg -
Serenoa repens 100 mg -
Equisetum arvense L. 7.14 mg -
Silicon 0.50 mg -
Zinc (zinc sulphate) 10 mg 100%
Vitamin B3 (nicotinamide) 16 mg 100%
Vitamin B5 (calcium D-
pantothenate)
6 mg 100%
Vitamin B6 (pyridoxine
hydrochloride)
1.4 mg 100%
D-biotin 50 µg 100%
Taurine 40 mg -
*Nutrient reference Value
Table 1: Product Composition.
Citation: Narda M, Aladren S, Cestone E, Nobile V (2017) Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens
Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial. J
Cosmo Trichol 3: 127. doi:10.4172/2471-9323.1000127
Page 2 of 8
J Cosmo Trichol, an open access journal
ISSN:2471-9323
Volume 3 • Issue 3 • 127
Endpoints
e primary outcome measured was the hair loss aer pull testing
for female subjects with aTE and the anagen/telogen hair ratio for male
subjects with AGA. All measurements were carried out on cleansed
hair (1 day before the visit) under temperature (22 ± 2°C) and
humidity (50 ± 10%) controlled conditions. Pull test (in female
subjects) consisted in a gentle traction exerted on a cluster of hair
(approximately 60 hairs) on three dierent areas of the scalp (frontal,
temporal, and occipital), and the number of hairs was counted.
Normally, less than three telogen-phase hairs should come out with
each pull. If at least three hairs were obtained with each pull or if more
than ten hairs total were obtained, the pull test was considered positive
and suggestive of telogen euvium.
For phototrichogram procedure (in male subjects), a transitional
area (1.8 cm²) of hair loss between normal hair and the balding area
was dened using a stencil template and chosen for clipping. e
clipped hairs within the target area were dyed for gray or fair hairs with
a commercially available solution (RefectoCil®, GW Cosmetics GmbH,
Leopoldsdorf, Germany) in order to enhance their contrast. ereaer,
the dyed hairs were cleansed using an alcoholic solution. Digital
macrophotographs were taken using a Nikon D300 reex camera
digital camera (Nikon Corporation Tokyo, Japan) equipped with a
macro objective (AF-S Micro NIKKOR 60 mm f/2.8G ED, Nikon
Corporation Tokyo, Japan), an independent ash system (Kit R1C1,
Nikon Corporation Tokyo, Japan) and cross-and parallel-polarized
lters. Digital macrophotographs were taken at the time of clipping (0
h) and 48 aerwards (48 h). e resulting images were analyzed by
using NIH soware. Aer identifying the same hairs in the images
taken at 0 h and 48 h following the clipping for all the experimental
monitored times, the length of each hair was measured and the
number of hair in the clipped area were counted. is allowed for the
calculation of the anagen (growing)/telogen (not growing) hair ratio.
e overall hair volume and overall hair appearance were assessed
by the dermatologist using a 7-point clinical score scale ranging from
-3 (greatly decreased or worsened) to 3 (greatly increased or
improved). e overall hair volume changes during the clinical trial
were assessed by the dermatologist on digital images.
Subjects also answered a 10 question questionnaire on eect of
treatment on aspects related to Quality of life (QoL) regarding hair loss
[14]. e responses were scored according to a 7 point scale ranging
from 1 (not aected at all) to 7 (extremely aected). A higher
numerical score indicated a greater concern and a lower numerical
score indicated a lesser concern for the items of the QoL questionnaire.
In addition, subjects were also asked to score product ecacy
according to a 10 points scale ranging from 1 (very poor) to 10 (very
good).
Sample size
Sample size was calculated with a two-sided 5% signicance level
and a power of 80% taking into account a 20% variation of the primary
endpoints due to both inter-individual human variability and error in
the measurement techniques. A sample size of 20 subjects per group
was necessary given an anticipated dropout rate of 20%.
Randomization
A restricted randomization list was generated using PASS 11
(version 11.0.8 for Windows; PASS, LLC. Kaysville, UT, USA) statistical
soware running on Windows Server 2008 R2 Standard SP1 64 bit
Edition (Microso, USA) by a biostatistician and stored in a safe place.
Randomization sequence was stratied using the biased coins Efron’s
algorithm with a 2:1 allocation ratio. e allocation sequence was
concealed from the in site study director in sequentially numbered,
opaque, and sealed envelopes, reporting the unblinded treatment
allocation (based on subject entry number in the study). e A4 sheet
reporting the unblinded treatment was folded to render the envelope
impermeable to intense light. Aer acceptance of the subject in the
study the appropriate numbered envelope was opened. An
independent technician dispensed either active or placebo products
according to the card inside the envelope. e study adhered to
established procedures to maintain separation between the investigator
and its collaborators and the sta that delivered the intervention.
Investigator and its collaborators who obtained outcome
measurements were not informed on the product group assignment.
Sta who delivered the intervention did not take outcome
measurements. Subjects, investigator and collaborators were kept
masked to products assignment.
Statistical Methods
Statistical analysis was performed using NCSS 8 (version 8.0.4 for
Windows; NCCS, LLC) running on Windows Server 2008 R2 64
Edition. Data normality was checked using Shapiro-Wilk W normality
test and data shape. A p value <0.05 was considered statistically
signicant. Intragroup comparisons for normally distributed data
(phototrichogram and pull test) were analyzed by two-way paired t
test. Intergroup comparisons for normally distributed data
(phototrichogram) were analyzed by two-way unpaired t test, while for
not normally distributed data a Mann-Whitney U test was performed.
Ecacy analyses were performed on the Per Protocol (PP) population,
i.e., on all subjects who completed the study without any major
protocol violations. Intergroup statistical analysis was performed on
baseline parameters. ere were no statistically signicant dierences
were between groups. Safety analyses were performed on the Safety
population, i.e. on all subjects who were assigned a subject number and
who received at least one dose of study treatment. For
phototrichogram results the percent variation was calculated as the
mean of each single variation for each treatment group.
Results
e study was conducted between March and September 2014. A
total of 70 subjects, 35 men and 35 women, were randomized in the
study, and 23 men and 23 women received the active treatment while
12 men and 12 women received the placebo (Figure 1). No major
deviation was observed in the treatment regimen. All subjects were
included in the safety analysis data set. In general, the treatment was
well tolerated. ere was only one premature study termination in 1
woman who received the active treatment, due to bloating symptoms.
Demographic and baseline characteristics (Table 2) were similar across
treatment arms, indicating an unbiased randomization and the
absence of covariates. No signicant dierences were observed
between the two groups (active and placebo) regarding age, scalp
conditions, hair length, and hair loss related parameters. Due to early
study termination, one female subject receiving the active treatment
was not included in the ecacy population. erefore this population
comprised 22 subjects in the active group and 12 in the placebo group.
All randomized male subjects were included in the ecacy population.
Citation: Narda M, Aladren S, Cestone E, Nobile V (2017) Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens
Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial. J
Cosmo Trichol 3: 127. doi:10.4172/2471-9323.1000127
Page 3 of 8
J Cosmo Trichol, an open access journal
ISSN:2471-9323
Volume 3 • Issue 3 • 127
Figure 1: Flow diagram of enrolment, intervention allocation, and data analysis.
Female subjects, N=35 Male subjects, N=35
Active
Treatment
N=23
Placebo
N=12
Active
Treatment
N=23
Placebo
N=12
Age 46.5 ± 2.6 44.2 ± 3.7 40.6 ± 2.5 46.4 ± 2.5
Scalp
condition
Sensitive skin 21.7% 16.7% 21.7% 33.3%
Normal skin 4.3% 16.7% 8.7% 8.3%
Oily skin 39.1% 25.0% 34.8% 33.3%
Burning, itching
sensation
4.3 8.3% 0.0% 0.0%
Sensitive skin,
stinging
sensation
4.3 0.0% 0.0% 0.0%
Sensitive skin,
Burning
sensation,
Itching
sensation
4.3 0.0% 0.0% 0.0%
Oily skin,
Desquamation
0.0% 8.3% 0.0% 0.0%
Sensitive skin,
itching
sensation
17.4% 0.0% 13.0% 0.0%
Desquamation 8.3% 8.7% 8.3%
Oily skin,
itching
sensation
0.0% 8.3% 0.0% 0.0%
Citation: Narda M, Aladren S, Cestone E, Nobile V (2017) Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens
Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial. J
Cosmo Trichol 3: 127. doi:10.4172/2471-9323.1000127
Page 4 of 8
J Cosmo Trichol, an open access journal
ISSN:2471-9323
Volume 3 • Issue 3 • 127
Dry dandruff,
itching
sensation
0.0% 8.3% 13.0% 16.7%
Hair Length
Short 4.3% 8.3% 95.7% 100%
Medium 65.2% 41.7% 4.3% 0.0%
Long 30.4% 50.0% 0.0% 0.0%
Hair Loss
Characteristic
s
Pull test 12.9 ± 0.4 12.8 ± 0.5 na na
AGA scoring n
(%)
II na na 7 (30.4%) 3 (25.0%)
III na na 8 (34.8%) 4 (33.3%)
III vertex na na 8 (34.8%) 5 (41.7%)
Anagen hair
(%)
na na 64.5% 63.9%
Telogen hair
(%)
na na 35.5% 36.1%
Data are means ± SE or percentage of subjects. na: not applicable.
Table 2: Demographic and baseline characteristics of study population.
Pull testing
e number of hairs removed in the pull test decreased steadily for
both treated and placebo group over the 6-month period.
Figure 2: Changes over time in Pull Test (female subjects). Data are
means ± SE of number of hair. *p<0.05 and **p<0.01 (active
vs.
placebo).
However, at 1 (M1), 3 (M3) and 6 (M6) months the decrease was
signicantly greater for the treated group compared to the placebo
group (p<0.05; Figure 2). At M3 and M6, the mean number of pulled
hairs was below the threshold for denition of aTE in the active
treatment group while this is the case only at 6 months in the placebo
group (Figure 2).
Phototrichogram
Endpoint Time Active Placebo
Anagen hair count M0 102.9 ± 2.2 102.1 ± 3.6
M3 102.9 ± 2.1 98.8 ± 4.9
M6 109.5 ± 2.1 101.1 ± 3.5
Telogen hair count M0 57.6 ± 3.4 57.5 ± 2.5
M3 56.6 ± 3.5 59.4 ± 2.2
M6 52.4 ± 3.8 58.8 ± 2.2
Anagen/telogen ratioaM0 1.93 ± 0.12 1.81 ± 0.11
M3 1.97 ± 0.13 1.71 ± 0.14
M6 2.36 ± 0.18** 1.75 ± 0.10
Table 3: Phototrichogram results (male subjects). Data are mean ± SE.
aAnagen/Telogen ratio=(Anagen hair count)/(Telogen hair count).
**p<0.01.
In men, there was a statistically signicantly increase (23.4%
increase) in the anagen/telogen ratio in the active treatment group at
M6 as compared with baseline (Table 3). ere was a statistically
signicant dierence (p<0.05) between the active treatment group and
the placebo with a +3.7% increase in the total percent of anagen hair in
the active treatment group from baseline to M6,
vs.
-0.8% decrease in
the placebo group, and a -3.7% decrease in the total percent telogen
hair in the active treatment group
vs.
a +0.8% increase in the placebo
group (Table 3).
Hair volume and hair aspect
Hair volume and hair aspect changes over time are reported in
Figure 3. For both women and men, a majority of subjects described an
increase in hair volume (slight or moderate) in the active treatment
group as compared with the placebo group from M3 (p<0.01) to M6
(p<0.01). e dierence
vs.
placebo was statistically signicant from
M1. Hair aspect was signicantly improved (p<0.05) at M6 with more
improved subjects in the active group as compared with the placebo
group.
Figure 3: Changes over time in overall hair volume and hair aspect
(female and male subjects). Data are % of subjects showing an
improvement. *p<0.05 and **p<0.01 (active
vs.
placebo).
Citation: Narda M, Aladren S, Cestone E, Nobile V (2017) Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens
Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial. J
Cosmo Trichol 3: 127. doi:10.4172/2471-9323.1000127
Page 5 of 8
J Cosmo Trichol, an open access journal
ISSN:2471-9323
Volume 3 • Issue 3 • 127
Quality of life
e cumulative results from QOL questionnaire showed an
improvement in the Lambdapil® treated group compared to baseline
values aer 3 and 6 months of treatment.
Month Active Placebo Intergroup stat.
analysis
0 19.7 ± 1.4 20.6 ± 2.6 n.s.
3 18.3 ± 1.2 28.5 ± 3.3 *
6 18.2 ± 1.2 24.0 ± 3.1 n.s.
Table 4: Quality of life questionnaire (male and female subjects). Data
are reported as the sum of the score given to each question ± SE.
Statistical analysis is reported as follows:*p<0.05 I.
is was opposed to the placebo group where a worsening in QOL
cumulative scores was at the same time points (Lambdapil®
vs.
placebo,
p<0.05 at 3 months; Table 4).
Self-Assessment of Ecacy All subjects responded to questionnaire
regarding their perception of ecacy of treatment. Results from the
questionnaire are presented in Table 5. Overall, Lambdapil® treated
subjects noticed a greater improvement in indicators of hair growth
compared to the placebo group.
Item Active (n=45) Placebo (n=25)
Have you noticed a decrease of
hairs loss?
66.7% (n=30) 54.2% (n=13)
Have you noticed the growth of new
hairs?
57.8% (n=23) 37.5% (n=9)
Have you noticed an increase of
hairs thickness?
57.8% (n=26) 37.5% (n=9)
Do your hairs grow faster? 62.2% (n=28) 58.3% (n=14)
Has the treatment reinforced your
hair?
68.9% (n=31) 41.7% (n=10)
Has the treatment increased of
brightness of hair?
64.4% (n=29) 45.8% (n=15)
Has the treatment increased hair
volume?
64.4% (n=29) 45.8% (n=11)
Has the treatment reinforced your
nails?
51.1% (n=23) 58.3% (n=14)
Table 5: Self-assessment questionnaire (male and female subjects).
Data are reported as % of subjects scoring product ecacy 6
(sucient).
Global photographic assessment
Figure 4 shows the macroscopic eect of the product on hair
volume. An increase in hair volume was seen in the frontal and parietal
area (vertex) of the scalp.
Digital photography-T0 baseline, T3 3 months, T6 6 months (a-b).
Figure 4: Digital photography. T0-baseline, T3-3 months, T6-6
months (a-b).
Discussion
ere is little doubt that nutrition inuences hair loss pathologies
[15,16] and that food supplements work on several factors of this
complex etiology can help in the management of hair loss [17,18]. is
randomized, double-blind, placebo-controlled trial studied the ecacy
of Lambdapil®, a food supplement containing
Serenoa Repens
and
Equisetum arvense
extract (rich in silicon), vitamins (B3, B5, B6, D-
Biotin), amino acids (L-cystine, taurine), and zinc, in women with aTE
and in men with AGA. aTE involves intense hair loss that usually lasts
a few months but is reversible. Women seem to be more prone to this
kind of hair loss that usually happens 2-5 months aer a trigger event.
Women suering from aTE nd the condition stressful as they notice a
large number of hair being lost daily. Although aTE eventually reverses
naturally, in the present study Lambdapil® supplementation helped the
reversal of this condition in a shorter time span compared to placebo
controls as evidenced by the results from the pull test.
In men with AGA, an increase of 23.4% in the anagen/telogen ratio
from baseline to the end of the 6-month treatment period was
observed in patients taking Lambdapil® whereas no such increase was
observed in the placebo group. e anagen hair count increase aer a
6-month period treatment corresponding to 6.7 new hairs in the area
of phototrichogram which when roughly extrapolated to whole scalp
area translates to 2,159 new hairs aer 6 month supplementation (scalp
area 580 cm2; RIVM data). In contrast, there was no increase in hair
count in placebo-treated subjects, even if a negative variation (not
statistically signicant) of anagen hair count was recorded.
Finally, body image is a psychological concept that refers to a
person’s perception related to his or her physical appearance. For many
people, hair is a physical attribute that forms a large part of the feeling
of attractiveness or unattractiveness. In this respect the ndings related
to improvement in both hair aspect and hair volume in Lambdapil®
Citation: Narda M, Aladren S, Cestone E, Nobile V (2017) Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens
Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial. J
Cosmo Trichol 3: 127. doi:10.4172/2471-9323.1000127
Page 6 of 8
J Cosmo Trichol, an open access journal
ISSN:2471-9323
Volume 3 • Issue 3 • 127
group are considered very relevant as are the improved score for the
subject’s self-perception of improvement in hair quality and strength
from the results of the survey that the subjects responded to.
Although many of the components of the food supplement used in
this study are supported by scientic literature for their use in
alleviating signs of alopecia, in our knowledge this is the rst report of
a controlled, randomized clinical study that reports benets for women
with aTE and men with AGA with supplementation with a product
that contains these ingredients. In Morgantil et al. a combination of
Serenoa repens
extract and gelatin-cystine
via
oral route, increase
signicantly (around 25%) hair number/cm² and total hair mass/cm²
vs.
placebo at 30 weeks in patients with androgenic alopecia [19].
Lambdapil® oral supplements had a good safety prole with only 1
adverse event reported. Although the drug treatments for alopecia
available today are ecacious against both male and female alopecia,
they are associated with sexual and non-sexual side eects reported in
younger men with nasteride [20]. Oral supplements such as
Lambdapil® are a practical option for persons wanting to address
alopecia but without the side eects associated with drugs.
e strength of this study was the high-level methodology
employed: placebo-controlled, double-blind, 6-month duration study;
use of digital photographs for assessments of changes in AGA.
Although the research has reached its aim, there were some
unavoidable limitations. Firstly, the use of the pull test to assess the
changes for aTE may be considered as a limitation, as it was described
to be a test dicult to standardize due to the intrinsic variability of the
technique [6]. We justify its use as the only parameter available to
assess aTE in a clinical setting. Secondly, the small sample size may be
considered a limitation. Even if a priori sample size was calculated, to
generalize the results for larger groups, the study should have involved
more participants in order to take into account possible faults of the
stratied random sampling design and the power of statistical tests.
Finally, the self-assessment questionnaire is subjective. However even if
the output of a self-assessment questionnaire is not robust itself, when
associated to clinical/instrumental measurements it is useful to
understand if products eects are perceived by the subjects
participating in the study.
In conclusion, the oral supplementation with Lambdapil® capsules,
for 6 months, was ecacious in improving the signs and symptoms
related to aTE in women and AGA in men, and was suitably well
tolerated with negligible adverse events. It appears to be a safe and
ecacious way to address hair loss that ts in comfortably with the
daily routines of persons suering from this condition.
Contributors
SA designed the study protocol and was responsible for manuscript
reviewing; EC performed the experiments. VN wrote the study
protocol/manuscript and was responsible for data analysis and
interpretation. MN was responsible for writing and reviewing the
manuscript.
Acknowledgements
e authors thank all of the Complife Italia sta who contributed to
and recruited subjects for this study for their professionalism and
support during the study development.
Conict of Interest and Funding
is study was funded by Isdin SA. Isdin SA was involved in the
design of the study protocol and provided the test products samples.
Employees of the Sponsor were not involved in data analysis. e
manuscript was prepared by Dr. Vincenzo Nobile. Isdin SA was
permitted to review the manuscript and suggest changes, but the nal
decision on content was exclusively retained by Dr. Vincenzo Nobile.
Dr. Vincenzo Nobile is the guarantor for this manuscript, and takes
responsibility for the integrity of the work as a whole. SA and MN
work for Isdin SA.
References
1. de Koning EB, Passchier J, Dekker FW (1990) Psychological problems
with hair loss in general practice and the treatment policies of general
practitioners. Psychol Rep 67: 775-778.
2. Cash TF (2001) e psychology of hair loss and its implications for
patient care. Clin Dermatol 19: 161-166.
3. Hadshiew IM, Foitzik K, Arck PC, Paus R (2004) Burden of hair loss:
stress and the underestimated psychosocial impact of telogen euvium
and androgenetic alopecia. J Invest Dermatol 123: 455-457.
4. Girman CJ, Hartmaier S, Roberts J, Bergfeld W, Waldstreicher J (1999)
Patient-perceived importance of negative eects of androgenetic alopecia
in women. J Womens Health Gend Based Med 8: 1091-1095.
5. França K, Rodrigues TS, Ledon J, Savas J, Chacon A (2013)
Comprehensive overview and treatment update on hair loss. J Cosmet
Dermatol Sci Appli 3: 1-8.
6. Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, et al.
(2011) Evidence-based (S3) guideline for the treatment of androgenetic
alopecia in women and in men. J Dtsch Dermatol Ges 6: S1-57.
7. Jain R, De-Eknamkul W (2014) Potential targets in the discovery of new
hair growth promoters for androgenic alopecia. Expert Opin er Targets
18: 787-806.
8. Rossi A, Mari E, Scarno M, Garelli V, Maxia C, et al. (2012) Comparitive
eectiveness of nasteride vs
Serenoa repens
in male androgenetic
alopecia: a two-year study. Int J Immunopathol Pharmacol 25: 1167-1173.
9. Sandhu NS, Kaur S, Chopra D (2010)
Equisetum arvense
: Pharmacology
and phytochemistry-A review. Asian J Pharmaceut Clini Res 3: 146-150.
10. McElwee KJ, Shapiro JS (2012) Promising therapies for treating and/or
preventing androgenic alopecia. Skin erapy Lett 17: 1-4.
11. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2010)
Scientic Opinion on the substantiation of health claims related to zinc
and maintenance of normal skin (ID 293), DNA synthesis and cell
division (ID 293), contribution to normal protein synthesis (ID 293,
4293), maintenance of normal serum testosterone concentrations (ID
301), “normal growth” (ID 303), reduction of tiredness and fatigue (ID
304), contribution to carbohydrate metabolism (ID 382), maintenance of
normal hair (ID 412), maintenance of normal nails (ID 412) and
contribution to normal macronutrient metabolism (ID 2890) pursuant to
Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 8: 1819.
12. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2009)
Scientic Opinion on the substantiation of health claims related to
vitamin B6 and protein and glycogen metabolism (ID 65, 70, 71),
function of the nervous system (ID 66), red blood cell formation (ID 67,
72, 186), function of the immune system (ID 68), regulation of hormonal
activity (ID 69) and mental performance (ID 185) pursuant to Article
13(1) of Regulation (EC) No 1924/2006 on request from the European
Commission. EFSA Journal 7: 1225.
13. Norwood OT (1975) Male pattern baldness: classication and incidence.
South Med J 68: 1359-1365.
14. Biondo S, Sinclair R (2010) Quality of Life in Australian Women with
Female Pattern Hair Loss. e Open Dermatol J 4: 90-94.
15. Rushton DH (2002) Nutritional factors and hair loss. Clin Exp Dermatol
27: 396-404.
Citation: Narda M, Aladren S, Cestone E, Nobile V (2017) Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens
Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial. J
Cosmo Trichol 3: 127. doi:10.4172/2471-9323.1000127
Page 7 of 8
J Cosmo Trichol, an open access journal
ISSN:2471-9323
Volume 3 • Issue 3 • 127
16. Haneke E, Baran R (2011) Micronutrients for hairs and nails. In:
Krutmann J, Humbert P (eds.) Nutrition for Helathy skin-Strategies for
clinical and cosmetics practices. Berlin Heidelberg: Springer 149-163.
17. Lengg N, Heidecker B, Burkhardt S, Trüeb RM (2007) Dietary
supplement increases anagen hair rate in women with telogen euvium:
results of a double-blind, placebo-controlled trial. erapy 4: 59-65.
18. Zanzottera F, Nobile V, Bizzaro B, Michelotti A (2017) Ecacy of a
Nutritional Supplement, Standardized in Fatty Acids and Phytosterols, on
Hair Loss and Hair Health in both Women and Men. J Cosmo Trichol 3:
121.
19. Morganti P, Fabrizi G, James B, Bruno C (1998) Eect of gelatin-cystine
and
Serenoa repens
extract on free radicals level and hair growth. J Appl
Cosmetol 16: 57-64.
20. Irwig MS (2015) Safety concerns regarding 5α reductase inhibitors for the
treatment of androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes
22: 248-53.
Citation: Narda M, Aladren S, Cestone E, Nobile V (2017) Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens
Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial. J
Cosmo Trichol 3: 127. doi:10.4172/2471-9323.1000127
Page 8 of 8
J Cosmo Trichol, an open access journal
ISSN:2471-9323
Volume 3 • Issue 3 • 127
... 14 Previously, SP in food supplements has been clinically evaluated for the prevention of hair loss in AGA subjects. [15][16][17] However, most clinical studies have been conducted on formulations of SP with vitamins and minerals, making it difficult to understand the magnitude of efficacy of SP alone. Hence, it is important to study the hair care potential of SP individually, using randomized clinical trials. ...
... In a randomized clinical trial, Narda et al reported that a food supplement containing 100 mg of SP showed significant improvement in the hair pull test compared to placebo. 15 In another prospective cohort study, a 24-week application of SP-containing hair lotion increased the total hair count in male AGA subjects by 4.9%. 17 In the self-assessment of perceived treatment efficacy, the VISPO oral group participants responded positively to the HGI and HGSS scores. ...
... Previously, SP extracts were used for longer durations to observe a significant change with respect to perceived efficacy and anagen induction. 15,26 Overall, these observations clearly suggest that prolonged treatment with VISPO formulations could stimulate hair growth in subjects. Although no adverse effects were recorded during the study, it should be noted that the study duration was short and the sample size was small. ...
Article
Full-text available
Purpose Androgenetic alopecia (AGA) is the most common type of hair loss in humans, affecting self-esteem and emotional well-being. This study aimed to assess the safety and efficacy of VISPOTM, a standardized saw palmetto oil (2–3% β-sitosterol), in subjects with mild-to-moderate AGA. Methods In a double-blind, placebo-controlled, four-arm clinical study, 80 healthy male and female subjects aged 18–50 years were randomly allocated (1:1:1:1) to receive either 400 mg capsules of VISPO or 5 mL of a topical formulation containing 20% VISPO or the respective placebo once daily for 16 weeks. The primary endpoints included hair count (hair comb and hair pull tests) and the self-assessment of perceived efficacy. Objective evaluation was performed using the global photographic assessment score. Hair density, thickness, and anagen/telogen ratio were evaluated using phototrichogram analysis. Results At the end of the study, oral and topical formulations of VISPO reduced hair fall by up to 29% (p<0.001) and 22.19% (p<0.01) from the baseline, respectively. Hair density increased by 5.17% and 7.61% in the oral and topical VISPO groups, respectively (p<0.001). In addition, oral ingestion of VISPO resulted in a marked reduction in serum dihydrotestosterone (DHT) levels in the subjects compared to placebo (p<0.001). However, the effect of the VISPO formulations on the anagen/telogen ratio was insignificant. No serious adverse effects were observed during the study. Conclusion VISPO formulations reduced hair fall and promoted hair regrowth and scalp appearance in AGA patients.
... The synergy and combination of ingredients in oral supplements can offer diverse beneficial properties: L-Cystine, Serenoa repens, Cucurbita pepo, and Pygeum africanum together with vitamin B and zinc can address HL by targeting diverse aspects of hair health, using a holistic approach to combat this common concern [13]. Serenoa repens is a plant of the Arecaceae's family, also known as Sabal serrulata. ...
Article
Full-text available
Chronic telogen effluvium (TE) and andro-genetic alopecia represent two prevalent forms of hair loss that can significantly impact individuals' quality of life. In-sufficiency of essential micronutrients has been associated with hair loss. The objective of this study was to evaluate the safety and efficacy of an oral supplement containing L-Cystine, Serenoa repens, Cucurbita pepo, Pygeum africanum, vitamins, and micronutrients in chronic TE (CTE) and an-drogenetic alopecia (AGA). Methods: Eighty patients of both sexes aged 18-60 years with CTE or AGA were randomized to receive one capsule daily of the oral supplement or placebo for 6 months. Dermatological evaluations, clinical pictures and phototrichograms were done at baseline, 3 months and 6 months. The overall hair volume and appearance were assessed before and after treatment as well as subject's self-assessment via standardized questionnaire. Results: Hair density increased by 9.9 hairs/cm 2 after 3 months and 12.3 hairs/cm 2 after 6 months in the oral supplement group and it is statistically significant when compared to placebo. Overall hair volume after 1, 3, and 6 months is better in the supplement group than in the placebo group. The oral supplement was well tolerated. No moderate or severe adverse events were reported. Conclusion: Oral supplementation can increase hair density, anagen hairs, and overall hair appearance in patients with AGA or CTE.
... However, in the event of inflammation, overproduced cytokines like IL-1 and TNFα are known to induce premature catagen, liberate Reactive Oxygen Species (ROS), cause apoptosis, and further propagate inflammation [31][32][33]. In recent years, evidence of the beneficial role of food supplements in subjects affected by hair loss (including acute telogen effluvium from various aetiology) is growing [34][35][36][37][38][39]. In a survey administered to 177 dermatologists attending a national dermatology conference in Riyadh (Saudi Arabia), 62% of the respondents recommended vitamins and minerals for acute telogen effluvium. ...
Article
Full-text available
Background: Hair loss is a not life-threatening dermatological condition with some physical effects but with more severe psychosocial consequences. Nutrition deficiencies have been associated to hair loss, opening the door for food supplement's use in decreasing hair loss.
... Serenoa repens, commonly known as saw palmetto (SP), was the 11th highest selling herbal supplement in the US in 2020 [59]. This supplement is derived from the berries of a palm-like plant that is native to Florida, and the southeastern US SP supplements are available in a variety of forms, including dried berries, powdered capsules, tablets, liquid tinctures, and liposterolic extracts. ...
Article
Full-text available
Herbal and dietary supplement (HDS) use has grown exponentially in the United States. Unfortunately, the incidence of HDS-related liver injury has proportionally increased. Despite the potential for certain HDSs to cause clinically significant liver injury, they are not regulated by the Food and Drug Administration. Recent efforts have been made to regulate HDSs but are far removed from the scrutiny of prescription medications. Scant literature exists on HDSs and their risks of causing liver injury. In this comprehensive review, we examine trends of HDS use in the United States and the pathophysiologic mechanisms of drug-induced liver injury (DILI) of certain HDSs. Finally, we review usage rates; benefits, if any; purported pathophysiology of DILI; and propensity for progression to fulminant hepatic failure of nine HDSs linked to clinically significant DILI.
Article
Objective Hair loss is a major source of psychological distress for affected people. Safe and natural ingredients are therefore needed to help reduce hair loss and stimulate hair growth. This pilot clinical study aimed at exploring the efficacy of a wheat polar‐lipid complex (WPLC, Ceramosides TM ), containing sphingolipids and digalactosyl diglycerides, on hair characteristics improvement in women showing acute hair shedding. Methods Sixty‐six women presenting a proportion of hair in the telogen phase greater than 15% were recruited and allocated to two groups, each including at least ten postmenopausal women. For 84 days, participants consumed 30 mg/day of the WPLC supplement, or the placebo. Their hair characteristics were assessed after 56 and 84 days using phototrichogram evaluations of hairs in anagen/telogen phases, measuring hair shedding by a pull test, hair diameter and elongation at break point, hair growth, and scalp sebum content. Hair density and volume were also clinically evaluated. All these parameters were also investigated in the subgroup of postmenopausal women. Results WPLC supplementation decreased telogen hair density/proportion while increasing the anagen hair density/proportion. These effects were significant compared to the placebo as early as within 56 days. It also led to reduced hair shedding upon pull test analyses. If no changes were evidenced in hair diameter, WPLC improved hair resistance to breakage and growth after 84 days. Clinical evaluations also showed hair density and volume improvement. Further, supplementation decreased scalp sebum content in women with oily hair. The beneficial effects were also observed in the subgroup of postmenopausal women. Finally, WPLC supplementation increased participants' perception of their hair conditions. Conclusion Through a reducing effect on hair shedding and a stimulating effect on hair reappearance and growth, WPLC dietary supplementation was shown to significantly reduce hair loss in women.
Article
Full-text available
Cystine-enriched food supplements are increasingly popular due to their beneficial health effects. However, the lack of industry standards and market regulations resulted in quality issues with cystine food products, including cases of food adulteration and fraud. This study established a reliable and practical method for determining cystine in food supplements and additives using quantitative NMR (qNMR). With the optimized testing solvent, acquisition time, and relaxation delay, the method exhibited higher sensitivity, precision, and reproducibility than the conventional titrimetric method. Additionally, it was more straightforward and more economical than HPLC and LC-MS. Furthermore, the current qNMR method was applied to investigate different food supplements and additives regarding cystine quantity. As a result, four of eight food supplement samples were found to be inaccurately labeled or even with fake labeling, with the relative actual amount of cystine ranging from 0.3% to 107.2%. In comparison, all three food additive samples exhibited satisfactory quality (the relative actual amount of cystine: 97.0–99.9%). Notably, there was no obvious correlation between the quantifiable properties (price and labeled cystine amount) of the tested food supplement samples and their relative actual amount of cystine. The newly developed qNMR-based approach and the subsequent findings might help standardization and regulation of the cystine supplement market.
Chapter
Non-communicable diseases, such as cardiovascular disease, cancer, diabetes, obesity, and hypertension, represent the cause of 60% of all deaths around the globe. With proper diet and natural dietary antioxidant supplements, these diseases can be prevented by up to 40% according to the British Nutrition Foundation. This book provides a comprehensive overview of the literature on the health benefits of natural dietary antioxidant supplements. It presents state-of-the-art research and information as well as the global regulations, labelling, and health claims of natural dietary antioxidant supplements. Written by expert authors, the wealth of research is arranged by disease type rather than by supplement type making it much more useful to the reader. Filling a gap in the literature, the book is aimed at researchers and professionals working in food chemistry, nutrition, and health benefits.
Article
Full-text available
Objetivo: Demonstrar a importância do uso de vitaminas e minerais em pacientes com eflúvio telógeno, ressaltando o favorecimento da melhora do quadro patológico do paciente. Metodologia: Realizou-se a busca de artigos sobre o tema nos periódicos disponíveis nas principais bases de dados em saúde, Medline, Google Acadêmico e Pubmed, nos idiomas português e inglês. Resultados: Observou-se que pacientes com eflúvio telógeno, na maioria dos casos, apresentam deficiência de ferro e zinco. Por meio de alguns dos estudos, foi possível observar que uma porcentagem um pouco maior de participantes que possuíam o distúrbio tinham deficiência de biotina, porém esse relato não possui muitas evidências, podendo estar relacionado ou não. Um grande percentual dos casos com eflúvio telógeno apresentam deficiência de vitamina D, enquanto que apenas uma minoria pode se observar uma deficiência de vitamina B12. Pacientes com eflúvio telógeno estão propensos a ter uma diminuição de nos níveis de ferritina. Em relação à deficiência de demais vitaminas, como vitamina A, vitamina E, ácido fólico e selênio, não foi possível detectar uma relação com a queda de cabelo e a deficiência das mesmas. Ficou evidenciado, em parte dos artigos revisados, que os pacientes apresentavam uma prevalência de deficiências proteicas graves, além de um déficit maior de aminoácidos. Conclusão: Embora a suplementação com vitaminas e minerais não apresente um resultado de grande impacto no tratamento da queda de cabelo, foram identificados alguns estudos que relatem a importância do uso das mesmas, necessitando de estudos mais a fundo sobre o assunto.
Chapter
Saw Palmetto or Serenoa repens (also known by its botanical name, Sabal serrulatum) is a plant of the Arecaceae’s family, and it is an American bushy dwarf palm tree and cabbage palm. It is endemic to the subtropical Southeastern United States, most commonly along the south Atlantic and Gulf Coastal plains and sandhills, and in the West Indies islands. The plant may grow to a height of 6 m, with leaves up to 1 m across; the berries are fleshy, about 2 cm in diameter, and blue-black in color [1].
Article
Full-text available
Introduction: Hair health concern is one of the most distressing conditions for a significant number of men andwomen of all ages. The unique current pharmacologic therapeutic options approved by Food and Drugadministration (FDA) are finasteride and topical minoxidil; however, these treatments may have side effects and maywork on just one cause of hair loss, without giving an exhaustive and complete results.Objective: The aim of this study was to evaluate the efficacy of a nutritional complex, combining omega 3-6-9,antioxidant, natural inhibitors of 5α-reductase and anti-inflammatory molecules in improving hair loss and hair healthparameter such as volume, strength and reduction of greasiness. Methods: This study was made up of two phases. The in vitro experiment aimed at evaluating the capacity of the nutritional complex to lower the enzyme 5α-reductase activity in culture of human keratinocytes. The in vivo study was performed on 30 volunteers who experienced a 6 months treatment with the nutritional complex. The evaluation of hair loss and hair health parameter was performed by trichoscopy, global photograph review and subject’s assessment. Results: The in vitro study showed the capacity of the nutritional formulation to inhibit the total 5α-reductasecomparable to finasteride and Serenoarepens. The global photograph assessment at T0 and T6 showed anincreased hair density on 83.3% of subjects and the preliminary results were already visible just after three months. Moreover, the trichoscopy demonstrates an increase of hair diameter and hair density, an improvement ofvascularization and a reduction of greasiness at the follicle level. The hair quality and hair loss reduction valued bythe subjects showed positive results confirming the photographic outcomes. Conclusions: This study proves the action of nutritional complex components, ß-sitosterosl with omega 3-6complex from Serenoarepens, linseed, borage, wheat oils, pine bark and rye grass in inhibition of the total 5α-reductase. Furthermore, both the reduction of hair greasiness and the improvement of hair quality demonstrate thatthis formulation is not only effective against 5α-reductase but it also exerts its properties in a complete manner byrestoring the physiologic condition of a healthy scalp. Moreover, it demonstrates the positive effects of this naturalcomplex supplementation on overall scalp coverage. Visibly there is an improvement of vascularization, hairdiameter and the reduction of hair loss perception.
Article
Full-text available
The influence of gelatin-cystine and serenoa repens on hair growth was studied through a long period application (50 weeks) of a new cosmeceutical lotion. On 48 volunteers (24 women and 24 men) aged between 21 and 38 years, affected by androgenetic alopecia (type III and IV according to Hamilton). 12 subjects also took a diet supplement (4 pills per day) based on gelatin- cystine. The solution and the diet supplement (placebo and active) were assigned in a randomized double-blind manner. Hair mass and the mean hair number were controlled according to Price et al. Exclusion criteria included use of topical or oral drug or diet supplement within the previous six months. The obtained results showed an increase of hair mass from 20 to 30% (p<0.005) together with a contemporary increase of hair number (from 17 to 27%) (p<0.005) compared to the placebo for subjects using the lotion only. With the diet supplement a further increase of 50% (p<0.005) in hair growth and a significant decrease of blood ROS (Reactive Oxigen Species) were obtained.
Article
Full-text available
Hair loss is one of the most common complaints among all patients consulting a dermatologist and is usually associated with severe psychological disturbances, distress and symptoms of depression. [1-3]. It can be temporary or long lasting. Diagnosis of hair loss is based on detailed clinical history, physical exam, clinical diagnostic tests, laboratory testing, and scalp biopsy, which may be necessary to confirm some diagnoses. This article presents an overview of the most common clinical causes of hair loss and provides updated information on the current available therapeutic options for these disorders.
Article
Full-text available
Background: Female pattern hair loss (FPHL) produces chronic progressive hair loss in women. The morbidity is predominately psychological. Empirical research investigating the psychological aspects of FPHL and the impact of initiation of treatment in Australian women is absent. Objective: To examine the impact of FPHL on the quality of life (QOL) and the impact of initiation of treatment on QOL. Method: 77 women with biopsy-proven FPHL receiving treatment with oral antiandrogens, 53 women on a waiting list to receive treatment for FPHL and 82 women not affected by hair loss completed the Women's AGA Quality of Life Questionnaire (WAA-QOL). Results: AGA affected women reported poorer health-related QOL than non-affected women. There was no change in QOL over a two-month period following assessment and initiation of treatment. The WAA-QOL was found to have excellent internal consistency (Cronbach's alpha = .97) and test-retest reliability (correlation coefficient = .92). Conclusion: The findings confirm the detrimental impact of FPHL on the QOL and the lack of impact of medical consultation and initiation of treatment on QOL at 2 months. This has implications for the treatment of psychological difficulties associated with FPHL and suggests a possible role for adjuvant psychological intervention.
Article
Full-text available
The objective of this open label study is to determine the effectiveness of Serenoa repens in treating male androgenetic alopecia (AGA), by comparing its results with finasteride. For this purpose, we enrolled 100 male patients with clinically diagnosed mild to moderate AGA. One group received Serenoa repens 320 mg every day for 24 months, while the other received finasteride 1 mg every day for the same period. In order to assess the efficacy of the treatments, a score index based on the comparison of the global photos taken at the beginning (T0) and at the end (T24) of the treatment, was used. The results showed that only 38% of patients treated with Serenoa repens had an increase in hair growth, while 68% of those treated with finasteride noted an improvement. Moreover finasteride was more effective for more than half of the patients (33 of 50, i.e. 66%), with level II and III alopecia. We can summarize our results by observing that Serenoa repens could lead to an improvement of androgenetic alopecia, while finasteride confirmed its efficacy. We also clinically observed, that finasteride acts in both the front area and the vertex, while Serenoa repens prevalently in the vertex. Obviously other studies will be necessary to clarify the mechanisms that cause the different responses of these two treatments.
Article
Full-text available
Androgenetic alopecia (AGA) may affect up to 70% of men and 40% of women at some point in their lifetime. While men typically present with a distinctive alopecia pattern involving hairline recession and vertex balding, women normally exhibit a diffuse hair thinning over the top of their scalps. The treatment standard in dermatology clinics continues to be minoxidil and finasteride with hair transplantation as a surgical option. Here we briefly review current therapeutic options and treatments under active investigation. Dutasteride and ketoconazole are also employed for AGA, while prostaglandin analogues latanoprost and bimatoprost are being investigated for their hair growth promoting potential. Laser treatment products available for home use and from cosmetic clinics are becoming popular. In the future, new cell mediated treatment approaches may be available for AGA. While there are a number of potential treatment options, good clinical trial data proving hair growth efficacy is limited.
Article
Equisetum arvense commonly known as field horsetail is a plant with wide prospectus. In folk medicine, Equisetum arvense is used for tuberculosis, as a catarrh in the kidney and bladder regions, as a hematostatic for profuse menstruation, nasal, pulmonary and gastric hemorrhages, for brittle fingernails and loss of hair, for rheumatic diseases, gout, poorly healing wounds and ulcers, swelling and fractures and for frostbite (PDR for herbal medicines). The plant is reported to contain a number flavonoids, alkaloids, minerals, phenolic petrosins, triterpenoids, saponins, phytosterols. The present review is an attempt to generate interest among the masses regarding its immense potential in preventing and treating several disorders.
Article
To examine the clinical and basic studies regarding persistent adverse effects associated with 5α reductase inhibitor treatment for androgenetic alopecia. Recent postmarketing reports and a US Food and Drug Administration analysis have documented uncommon persistent sexual and nonsexual side-effects in a subset of younger men who have taken finasteride 1 mg for androgenic alopecia. While the mechanisms of the sexual side-effects in humans is incompletely understood, one study found lower cerebrospinal fluid concentrations of dihydrotestosterone, progesterone, dihydroprogesterone and allopregnanolone, and higher levels of testosterone, 5α-androstane-3α,17β-diol and pregnenolone. Another study found up-regulation of the androgen receptor in the human foreskin with a mean of 5 years after finasteride discontinuation. Studies of erectile dysfunction in finasteride-treated rats showed fewer autophagosomes in smooth muscle on transmission electron microscopy, increased apoptosis, decreased smooth muscle, increased collagen deposition and decreased endothelial nitric oxide synthase. Finally, 5α reductase inhibitors have also been found to alter semen parameters in healthy men. Multiple animal studies provide a biological basis for many of the persistent effects seen in humans such as erectile dysfunction, depression and decreased alcohol consumption. Prescribers of 5α reductase inhibitors should discuss the potential risks with their patients seeking treatment for androgenetic alopecia.
Article
Introduction: Androgenic alopecia (AGA) is the major type of scalp hair loss affecting 60 - 70% of the population worldwide. It is caused by two potent androgens, namely testosterone (T) and 5α-dihydrotestosterone (5α-DHT). Till date, only two FDA-approved synthetic drugs, minoxidil and finasteride, are used to cure AGA with only 35 and 48% success, respectively; therefore, a search for new drug based on the mechanism of androgens action is still needed. Areas covered: Relevant literature was reviewed to identify current therapeutic targets and treatments for AGA. The potential targets are classified into three categories: i) 5α-reductase; ii) androgen receptor and iii) growth-factor-producing genes related to hair growth. Expert opinion: Relevant assay systems using the right targets are required in order to obtain specific and effective drugs for AGA treatment. It is unlikely that single targeted agents will be sufficient for treating AGA, and therefore, it would be a challenge to obtain compounds with multiple activities.
Article
BACKGROUND: Dietary supplements are traditionally used over-the-counter products for the treatment of hair loss. OBJECTIVES: We aim to examine the effect of a specific L-cystine, medicinal yeast, pantothenic acid complex-based dietary supplement (Pantogar®) on telogen effluvium in healthy women. METHODS: A randomized, double-blind, placebo-controlled study was conducted over 6 months in 30 healthy women suffering from telogen effluvium. The efficacy of the supplement was evaluated by means of digitalized epiluminescent microscopy (TrichoScan) performed before treatment and after 3 and 6 months. Additionally, global photographs were taken and evaluated by independent investigators. RESULTS: Active compound led to a statistically significant improvement and normalization of the mean anagen hair rate within 6 months of treatment (p = 0.003), while there was no significant change in the placebo group (p = 0.85). These changes of the anagen hair rates were significantly different (p = 0.008). The appearance of hair growth in the global photographic assessment was judged better in the active compound than in the placebo group. CONCLUSIONS: This is the first study performed combining epiluminiscence microscopy with digital image analysis to demonstrate that a dietary supplement influences hair growth. The mode of action is not known, although it seems to result from an induction of anagen.